Oncolytics secured acceptance of two abstracts for AACR 2026, detailing how pelareorep engages innate and adaptive immunity via double-stranded RNA signaling. Data highlight coordinated interferon production, dendritic cell activation and cytotoxic T-cell priming driving tertiary lymphoid structure formation across breast and gastrointestinal tumor samples.

Biomarker results from cohort 1 of the Phase 1/2 GOBLET trial combining pelareorep with atezolizumab, gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma demonstrated a 62% objective response rate. Patients exhibiting an immune activation signature at Week 4 achieved median progression-free survival of 7.5 months versus 5.6 months in non-activated counterparts.

Imaging mass cytometry in the AWARE-1 window-of-opportunity study identified cellular neighborhoods of T cells, B cells, dendritic cells and macrophages evolving into tertiary lymphoid structures in early-stage breast cancer biopsies. Findings suggest pelareorep can convert immunologically cold tumors into hot, potentially enhancing response to subsequent immunotherapies.